SAN FRANCISCO — In a high-stakes litigation showdown in the burgeoning market for non-invasive prenatal testing, Illumina Inc. has scored a patent infringement verdict against rival Ariosa Diagnostics.
A federal jury found that Ariosa’s Harmony test infringed two of Illumina’s gene-sequencing patents. The jury awarded $26.7 million in damages, about a quarter of the $104 million Illumina wanted. Perhaps more importantly, the jury found that the latest version of Ariosa’s test infringes Illumina’s patented gene-sequencing technology. That finding leaves open the possibility that Illumina can seek an injunction from U.S. District Judge Susan Illston of the Northern District of California.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]